Intermittent Fasting for Health & Longevity - Quick Reference Sheet

Intermittent Fasting for Health & Longevity

Created on 08/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Fasting changes when food is eaten, not what. Human evidence supports modest weight and fat loss, steadier blood sugar, better blood fats and blood pressure, and less liver fat — working about as well as eating fewer calories. Longevity claims stay unproven in people. Main downsides: early hunger, muscle loss, and risks for those on medication. (Full Review)

Protocol

Time-Restricted Eating
16:8 or 14:10
All food within an 8–10 hour daily window; most widely used and best tolerated
5:2 Modified Fasting
5 normal, 2 low days
~500–600 kcal on two non-consecutive days weekly
Alternate-Day Fasting
Fast / feed days
~500 kcal or little food on fast days; slight edge for weight loss but harder to sustain
Time to effect
Weight & Blood Sugar
4–12 weeks
Measurable weight loss and blood-sugar improvements appear
Liver & Lipids
Over months
Liver-fat and blood-fat benefits accrue gradually
Fat-Burning & Appetite
Days–2 weeks
Fat-burning and appetite adaptation typically begin

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Type 1 diabetes
  • Current or past eating disorder
  • Underweight (BMI < 18.5)
  • Children and adolescents
  • Frail older adults
  • Advanced kidney or liver disease
Key Interactions
  • Insulin and sulfonylureas (glipizide, glyburide, glimepiride)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin) and metformin
  • Blood-pressure medications (ACE inhibitors, diuretics, beta-blockers)
  • Medications requiring food (NSAIDs, doxycycline, levothyroxine)
  • Warfarin and other narrow-margin drugs
  • Lithium
  • Caffeine, alcohol, and NSAIDs
  • Additive glucose- or pressure-lowering supplements (berberine, chromium, cinnamon extract, high-dose magnesium)
  • Fat-soluble vitamins and minerals (A, D, E, K; iron, magnesium)

Risk & Side Effects

  • High: Hunger, fatigue, and irritability during adaptation; compensatory overeating and reduced diet quality
  • Medium: Loss of lean muscle mass; hypoglycemia in people on glucose-lowering medication; triggering or worsening disordered eating
  • Low: Headaches, constipation, and sleep disturbance; menstrual and hormonal disruption in women; gallstone formation with rapid weight loss
  • Speculative: Cardiovascular risk with very short eating windows; reduced bone mineral density

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks blood-sugar control and fasting response
HbA1c 4.8–5.4% Average blood sugar over ~3 months; key metabolic marker
Fasting insulin 2–5 µIU/mL Detects insulin resistance earlier than glucose
Triglycerides <80 mg/dL Reflects metabolic and lipid response to fasting
HDL cholesterol >55 mg/dL (>60 in women) "Good" cholesterol; cardiovascular protection
LDL cholesterol Context-dependent "Bad" cholesterol; cardiovascular risk
hs-CRP <1.0 mg/L (optimal <0.5) Marker of systemic inflammation
ALT / AST <25 U/L (ALT) Liver enzymes; track fatty-liver improvement
Blood pressure <120/80 mmHg Monitors cardiovascular benefit and over-lowering
Body composition (DEXA) Maintain or increase lean mass Ensures weight lost is fat, not muscle
Electrolytes (sodium, potassium, magnesium) Mid-normal range Guards against depletion during longer fasts

Cadence: Baseline, then ~8–12 weeks, then every 6–12 months; more frequent glucose checks when adjusting diabetes medication.

Qualitative Assessment

  • Energy and focus: stable daytime energy and mental clarity
  • Sleep quality: falling asleep easily and sleeping through the night
  • Hunger and relationship with food: manageable hunger without preoccupation, bingeing, or anxiety around eating
  • Physical performance: maintained strength and exercise capacity
  • Mood and adherence: a sustainable pattern that does not worsen mood or social life